文献速递炎症性肠病肝病

口服万古霉素与原发性硬化性胆管炎相关炎症性肠病临床结局改善相关:来自儿童PSC联盟的匹配分析

Oral vancomycin is associated with improved inflammatory bowel disease clinical outcomes in primary sclerosing cholangitis-associated inflammatory bowel disease (PSC-IBD): A matched analysis from the Paediatric PSC Consortium.
PubMed 文献 · Aliment Pharmacol Ther · 2024-03-10

该回顾性多中心队列研究基于儿童PSC联盟数据,按结局评估时IBD病程1:3匹配万古霉素治疗与未治疗患者,发现万古霉素与IBD临床缓解及内镜缓解的更高比值相关,并伴有CRP降低和血红蛋白、白蛋白升高。

要点

  • 匹配队列中万古霉素组70例、未治疗组210例,临床缓解比值比OR 3.52(95%CI 1.97-6.31),校正后aOR 5.24(95%CI 2.68-10.22)。
  • 内镜缓解校正后aOR 2.76(95%CI 1.002-7.62),有数据者N=101;CRP降低(p=0.03),血红蛋白和白蛋白升高(均p<0.01)。
  • 作者结论认为需进一步开展随机对照研究,以客观黏膜炎症标志物明确疗效、评估安全性并确定最佳剂量。

核心结论

  • 万古霉素与IBD临床缓解及内镜缓解的更高比值相关。
  • 需要进一步开展随机对照研究,以客观黏膜炎症标志物明确疗效、评估安全性并确定最佳剂量。

研究设计与样本

  • 回顾性多中心队列研究,使用儿童PSC联盟数据。
  • 按主要结局评估时IBD病程1:3匹配万古霉素治疗与未治疗患者。
  • 匹配队列包括70例万古霉素治疗和210例未治疗患者。
  • 113例PSC-IBD患者接受万古霉素,中位年龄12.7岁,63%为男性。
  • 使用广义估计方程(GEE)分析万古霉素与PGA缓解的关联,校正IBD类型、严重程度和药物暴露。

主要发现

  • 万古霉素与IBD临床缓解的更高比值相关:OR 3.52(95%CI 1.97-6.31),校正后aOR 5.24(95%CI 2.68-10.22)。
  • 在仅限非移植患者和基线中重度PGA患者的敏感性分析中,获益持续存在。
  • 万古霉素与内镜缓解的更高比值相关:aOR 2.76(95%CI 1.002-7.62),有数据者N=101。
  • 万古霉素与较低的CRP相关(p=0.03),与较高的血红蛋白和白蛋白相关(均p<0.01)。

局限性

  • 原文未报告局限性;结论中作者提出需要进一步开展随机对照研究,以客观黏膜炎症标志物明确疗效、评估安全性并确定最佳剂量。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Data on oral vancomycin for primary sclerosing cholangitis (PSC)-associated inflammatory bowel disease (IBD) are limited. AIMS: Using data from the Paediatric PSC Consortium, to examine the effect of vancomycin on IBD activity. METHODS: In this retrospective multi-centre cohort study, we matched vancomycin-treated and untreated patients (1:3) based on IBD duration at the time of primary outcome assessment. The primary outcome was Physician Global Assessment (PGA) of IBD clinical activity after 1 year (±6 months) of vancomycin. We used generalised estimating equations (GEE) to examine the association between vancomycin and PGA remission, adjusting for IBD type, severity and medication exposures. Secondary outcomes included serum labs and endoscopic remission (global rating of no activity) among those with available data and also analysed with GEE. RESULTS: 113 PSC-IBD patients received vancomycin (median age 12.7 years, 63% male). The matched cohort included 70 vancomycin-treated and 210 untreated patients. Vancomycin was associated with greater odds of IBD clinical remission (odds ratio [OR] 3.52, 95% CI 1.97-6.31; adjusted OR [aOR] 5.24, 95% CI 2.68-10.22). Benefit was maintained in sensitivity analyses restricted to non-transplanted patients and those with baseline moderate-severe PGA. Vancomycin was associated with increased odds of endoscopic remission (aOR 2.76, 95% CI 1.002-7.62; N = 101 with data), and with lower CRP (p = 0.03) and higher haemoglobin and albumin (both p < 0.01). CONCLUSION: Vancomycin was associated with greater odds of IBD clinical and endoscopic remission. Additional, preferably randomised, controlled studies are needed to characterise efficacy using objective markers of mucosal inflammation, and to examine safety and define optimal dosing.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Ricciuto A, Liu K, El-Matary W, et al. Oral vancomycin is associated with improved inflammatory bowel disease clinical outcomes in primary sclerosing cholangitis-associated inflammatory bowel disease (PSC-IBD): A matched analysis from the Paediatric PSC Consortium. Aliment Pharmacol Ther. 2024. PMID: 38462727. doi:10.1111/apt.17936

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。